Y-MABS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.21 USD | -0.17% |
|
+13.15% | +152.35% |
Presenter SpeechUnknown Executive (Executives)Welcome, everybody, to the 2022 Y-mAbs R&D Day. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Calendar
08:00am
- Q1 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
17.21
USD
Average target price
21.67
USD
Spread / Average Target
+25.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +152.35% | 755M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +8.88% | 23.47B | |
| -13.89% | 21.9B | |
| -5.89% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Transcript : Y-mAbs Therapeutics, Inc. - Special Call